Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Farmers Insurance
Mallinckrodt
Chubb
Argus Health
Fish and Richardson
McKinsey
Moodys

Generated: July 22, 2018

DrugPatentWatch Database Preview

Tris Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for TRIS PHARMA INC, and what generic alternatives to TRIS PHARMA INC drugs are available?

TRIS PHARMA INC has twenty-six approved drugs.

There are seven US patents protecting TRIS PHARMA INC drugs.

There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and nineteen supplementary protection certificates in eight countries.

Summary for Tris Pharma Inc
International Patents:19
US Patents:7
Tradenames:25
Ingredients:24
NDAs:26
Drug Master File Entries: 5
Patent Litigation for Tris Pharma Inc: See patent lawsuits for Tris Pharma Inc

Drugs and US Patents for Tris Pharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc LEVETIRACETAM levetiracetam SOLUTION;ORAL 090461-001 Sep 30, 2010 AA RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Tris Pharma Inc HYDROCODONE BITARTRATE AND ACETAMINOPHEN acetaminophen; hydrocodone bitartrate TABLET;ORAL 202214-001 Mar 27, 2013 AA RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Tris Pharma Inc TUZISTRA XR chlorpheniramine polistirex; codeine polistirex SUSPENSION, EXTENDED RELEASE;ORAL 207768-001 Apr 30, 2015 DISCN Yes No 8,790,700 ➤ Try a Free Trial Y ➤ Try a Free Trial
Tris Pharma Inc TUZISTRA XR chlorpheniramine polistirex; codeine polistirex SUSPENSION, EXTENDED RELEASE;ORAL 207768-001 Apr 30, 2015 DISCN Yes No 8,062,667 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Tris Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
8,491,935 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Tris Pharma Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0026 France ➤ Try a Free Trial PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
00085 Netherlands ➤ Try a Free Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C0008 Belgium ➤ Try a Free Trial PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
2013 00059 Denmark ➤ Try a Free Trial PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Fish and Richardson
Chinese Patent Office
Daiichi Sankyo
Healthtrust
US Army
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.